Freestone Grove Partners LP Biomarin Pharmaceutical Inc Transaction History
Freestone Grove Partners LP
- $13.2 Trillion
- Q2 2025
A detailed history of Freestone Grove Partners LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 335,513 shares of BMRN stock, worth $18.6 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
335,513Holding current value
$18.6 Million% of portfolio
0.14%Shares
1 transactions
Others Institutions Holding BMRN
# of Institutions
674Shares Held
185MCall Options Held
1.31MPut Options Held
1.1M-
Black Rock Inc. New York, NY22.7MShares$1.26 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.05 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$874 Million0.71% of portfolio
-
Dodge & Cox San Francisco, CA15.1MShares$837 Million0.5% of portfolio
-
Viking Global Investors LP12.3MShares$681 Million2.14% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.3B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...